[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Suzhou Municipal Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":150},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,47,77,99,127],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100537894","focused-power-ultrasound-mediated-inferior-perirenal-adipose-tissue-modification-therapy-for-essential-hypertension-paradise-htn-iii-100537894",false,"NCT06283758","Focused Power Ultrasound Mediated Inferior Perirenal Adipose Tissue Modification Therapy for Essential Hypertension (PARADISE HTN-III)","Focused Power Ultrasound Mediated Inferior Perirenal Adipose Tissue Modification Therapy for Essential Hypertension: a Multicenter, Randomized, Controlled Phase II\u002FIII Clinical Trial (PARADISE HTN-III)","Inclusion Criteria:\n\n1. Individual with office systolic blood pressure (SBP) ≥ 140 mmHg and \\\u003C160 mmHg, and office diastolic blood pressure (DBP)\\\u003C100mmHg after standardized antihypertensive drug treatment for 1 month;\n2. Individual with 24-hour Ambulatory Blood Pressure Monitoring (ABPM) average systolic blood pressure (ASBP) ≥130 mmHg；\n3. The anteroposterior, transverse and axial diameters of inferior perirenal fat pad measured by ultrasound should be at least 20mm；\n4. Individual is willing to sign the informed consent of the study.\n\nExclusion Criteria:\n\n1. Individual diagnosed as secondary hypertension (e.g. renal parenchymal hypertension, renal artery stenosis, primary aldosteronism, pheochromocytoma, Cushing's syndrome, aortic coarctation, obstructive sleep apnea hypopnea syndrome)；\n2. Individuals with ≥ 3 cardiovascular risk factors (male\\>55 years old, female\\>65 years old; smoking or passive smoking; 2-hour postprandial blood glucose 7.8-11mmol\u002FL and\u002For impaired fasting glucose (6.1-6.9mmol\u002FL); LDL-C ≥ 3.4mmol\u002FL (130mg\u002Fdl), HDL-C\\\u003C1.0mmol\u002FL (40mg\u002Fdl) or TC ≥ 5.2mmol\u002FL (200mg\u002Fdl); Family history of early onset of cardiovascular disease, age of onset of first degree relatives\\\u003C50 years old; Abdominal obesity, waist circumference: male\\>90cm, female\\>85cm or BMI\\>28kg\u002Fm2) or hypertensive target organ damage;\n3. riser hypertension (defined as night blood pressure higher than daytime blood pressure by ABPM)\n4. Regular night shift workers\n5. Individuals taking other medications that may affect blood pressure (such as glucocorticoids);\n6. Individual with history of kidney or kidney surrounding tissue surgery;\n7. Individuals with impairment of liver or kidney function (ALT, AST or creatinine greater than 2 times of the upper limit of normal reference);\n8. Individual with myocardial infarction, unstable angina pectoris, cerebrovascular accident or transient ischemic attack within 6 months of enrollment;\n9. Individual with type 1 diabetes or uncontrolled type 2 diabetes；\n10. Individual with uncontrolled thyroid dysfunction;\n11. Individual with urinary calculi or hematuria；\n12. Individual with atrial fibrillation;\n13. Individual with severe structural heart disease (e.g. valvular heart disease, cardiomyopathy, congenital heart disease);\n14. Individual with second degree and above atrioventricular block and\u002For sick sinus syndrome;\n15. Individual with abnormal coagulation function;\n16. Individual with infected waist skin;\n17. Individual with claustrophobia；\n18. Individual with malignant tumor;\n19. History of allergy to amlodipine, olmesartan, and hydrochlorothiazide\n20. Individual is pregnant, nursing or planning to be pregnant;\n21. Individual is unwilling to sign informed consent;\n22. Individual fails to complete the screening period.","ALL","18 Years","65 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","This seamless two-stage phase II\u002FIII clinical trial aims to evaluate the efficacy and safety of a novel focused power ultrasound mediated inferior perirenal adipose tissue modification therapy for essential hypertension. Stage 1 is a phase II, multicenter, open-label, randomized trial to determine the optimal treatment strategy. Stage 2 is a phase III, multicenter, randomized, double-blind trial investigating the efficacy and safety of optimal treatment strategy compared to sham control.",[27,28,29],"Hypertension","Blood Pressure","Cardiovascular Diseases",[27,31,32,33],"Cardiovascular diseases","Focused ultrasound","Novel method","RECRUITING","2026-01-21",{"date":37,"type":38},"2026-01-23","ACTUAL",{"date":40,"type":38},"2024-03-01",{"date":42,"type":21},"2026-10",{"name":44,"class":45},"Suzhou Municipal Hospital","OTHER",4,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":54,"minAge":4,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":59,"conditions":60,"keywords":64,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},"100574069","a-technique-improves-urinary-continence-in-patients-undergoing-laparoscopic-radical-prostatectomy-100574069","NCT06754488","A Technique Improves Urinary Continence in Patients Undergoing Laparoscopic Radical Prostatectomy","A New Vesicocervical Urethral Reconstruction Technique Improves Urinary Continence in Patients After Laparoscopic Radical Prostatectomy: a Single-center Randomized Controlled Trial","Inclusion Criteria:\n\n(1) Preoperative needle biopsy confirmed prostate cancer; (2) The clinical stage is T1 and T2\n\nExclusion Criteria:\n\n(1) Diseases that significantly increase the risk of surgery or anesthesia, such as severe cardiovascular diseases, respiratory diseases, and coagulation disorders. (2) Patients with extensive bone metastasis or metastases to other organs (3) patients with a history of urinary incontinence and transurethral resection of the prostate. (4) Tumor invasion of bladder neck.","MALE","79 Years",{"count":57,"type":21},120,[24],"Laparoscopic radical prostatectomy (LRP) is the main treatment method for early prostate cancer, and postoperative urinary incontinence is one of the main complications after LRP. Urologists have applied various new operations in clinical practice to improve the urinary incontinence of patients after LRP surgery, but urinary incontinence is still the main problem affecting the quality of life of patients after surgery. In recent years, we have found that the new bladder neck urethral reconstruction method adopted by our department in LRP surgery can effectively improve the postoperative urinary incontinence of patients. In this study, a randomized controlled trial was intended to verify that the new bladder and neck urethral reconstruction technique could effectively improve early urinary control in patients after radical laparoscopic prostatectomy, and the patients were randomly divided into four groups by factorial design: posterior reconstruction group, posterior reconstruction +anterior suspension group, Sham group, and anterior suspension group to further verify the influencing factors of improved urinary control. The aim is to prove that the new operation can effectively reduce the urinary incontinence rate of patients after LRP, and analyze the mechanism of the new operation to improve the urinary incontinence of patients after LRP, and provide a new idea for the reconstruction of bladder neck and urethra during laparoscopic radical prostatectomy.",[61,62,63],"Posterior Bladder Wall Reconstruction","Anterior Bladder Wall Reconstruction","Anterior Bladder Wall Suspension",[65,66,67],"prostate cancer","early urinary continence","laparoscopic radical prostatectomy","2024-12-23",{"date":70,"type":38},"2024-12-31",{"date":72,"type":21},"2025-01-01",{"date":74,"type":21},"2026-12-30",{"name":44,"class":45},1,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":76},"100535249","the-effect-of-lipus-on-the-maturation-of-newly-constructed-autogenous-avf-100535249","NCT06249373","The Effect of LIPUS on the Maturation of Newly Constructed Autogenous AVF","A Multicenter Randomized Controlled Trial on the Effect of Low-intensity Pulsed Ultrasound on the Maturation of Newly Constructed Autogenous Arteriovenous Fistulas in Uremic Patients","Inclusion Criteria:\n\n1.18 years old ≤ Age ≤ 75 years old, regardless of gender or ethnicity;\n\n2.Dialysis or non-dialysis patients who have newly established autologous arteriovenous fistula in the wrist and have not yet used the fistula for hemodialysis treatment;\n\n3.Before establishing an autologous arteriovenous fistula in the wrist, ultrasound examination will be performed. The radial artery diameter at the intended surgical site is\\>1.5mm, and the head vein diameter is\\>2mm （using a tourniquet）. The arterial and venous blood flow are unobstructed, and the distance between the vein and the skin is\\\u003C6mm;\n\n4\\. After introducing dialysis, the calcium ion concentration in the dialysate will be maintained at 1.5mmol\u002FL during the dialysis period, and low molecular weight heparin will be used for anticoagulation. The dosage of low molecular weight heparin remains unchanged （±1000U） during the study period;\n\n5\\. Sign an informed consent form.\n\nExclusion Criteria:\n\n1. Poor healing of internal fistula surgical incision;\n2. Active bacterial or viral infections;\n3. Pregnant women;\n4. The patient underwent kidney transplantation or was transferred to peritoneal dialysis during the study period;\n5. Subject ALT, AST ≥ 3 × upper limit of normal values;\n6. Within 3 months, according to NYHA classification, heart function is classified as level III-IV;\n7. Newly diagnosed unstable angina and cerebrovascular events within 3 months;\n8. Blood pressure below 90\u002F60mmHg or above 180\u002F100mmHg in the past 2 weeks;\n9. During the study period, patients did not follow medical advice and arbitrarily changed the types and dosages of other anticoagulants or anticoagulants (such as aspirin, clopidogrel, Agat Roban, etc.);\n10. Combine the use of glucocorticoids and immunosuppressants, such as tacrolimus, cyclosporine, MMF, azathioprine, leflunomide, Tripterygium wilfordii glycosides, etc;\n11. Other researchers consider inappropriate situations, such as coexisting with malignant tumors, where the expected lifespan is less than 6 months;\n12. I have participated in other clinical trials within 4 weeks prior to the start of this study.","75 Years",{"count":86,"type":21},300,[24],"This study aims to evaluate the effect of 12 week low-intensity pulse ultrasound (LIPUS) intervention on the maturation of newly constructed autologous arteriovenous fistulas in uremic patients. This study is a prospective, blinded, randomized controlled trial. This trial is divided into two stages. The first stage is a concept validation trial, which is a single center, prospective, blinded, randomized controlled clinical study. Subjects who meet the screening criteria are randomly divided into an intervention group and a control group in a 1:1 ratio. All subjects underwent safety and efficacy evaluations at the 2nd, 4th, 8th, 12th, and 4th week after treatment. After completing a 4-week follow-up of the 20th study subject, an analysis was conducted with the preset goal of achieving a higher maturation rate of arteriovenous fistula in the intervention group compared to the control group at the follow-up point, and the safety of the study was evaluated. The second stage is a key trial, which is a multicenter, prospective, blinded, randomized controlled clinical study. The inclusion criteria, primary and secondary endpoints, and safety endpoints of the study subjects remain unchanged, and the safety and efficacy of the overall population are evaluated.",[90],"Uremia; Chronic","2024-05-13",{"date":93,"type":38},"2024-05-16",{"date":95,"type":38},"2024-02-26",{"date":97,"type":21},"2026-12-31",{"name":44,"class":45},{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":111,"conditions":112,"keywords":115,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":4},"100538660","early-phase-1-safety-and-efficacy-study-of-nggt006-in-refractory-hypercholesterolemia-patients-100538660","NCT06293729","Safety and Efficacy Study of NGGT006 in Refractory Hypercholesterolemia Patients","A Clinical Study for the Safety and Efficacy of Intravenous Infusion of NGGT006 in Treatment of Refractory Hypercholesterolemia","Inclusion Criteria:\n\n1. 18 ≤ age ≤ 55 years old;\n2. A patient with a clear diagnosis of refractory hypercholesterolemia and confirmed by genetic testing to be familial hypercholesterolemia;\n3. AAV binding antibody titer ≤1:80 and AAV neutralizing antibody ≤1:5;\n4. 18≤BMI (body mass index)≤35;\n5. During the screening period, the subjects have received stable maximum tolerated dose of lipid-lowering drug treatment, but LDL-C was still ≥70mg\u002FdL with clinical atherosclerotic cardiovascular disease; or LDL-C level was ≥ 100 mg\u002FdL without clinical atherosclerotic cardiovascular disease: the highest tolerated dose refers to (the following must be met at the same time):\n\n   ① Moderate to high doses of statins for ≥4 weeks, whether used alone or in combination with other lipid-lowering drugs; exceptions: subjects cannot tolerate statins; or subjects cannot receive statin treatment due to other reasons, such as low BMI, etc.;\n\n   ② Ezetimibe ≥ 4 weeks;\n\n   ③ Alirocumab 150mg Q2W or 300mg Q4W; evolocumab 140mg Q2W or 420mg Q4W; ≥8 weeks; And during the clinical trial process, any adjustment involving the type and dosage of lipid-lowering drugs must be approved by the researcher;\n6. Stable healthy diet for ≥12 weeks, and can adhere to a healthy diet throughout the entire clinical trial;\n7. Voluntarily sign the informed consent form and be willing to comply with the trial visit plan;\n8. Willing to maintain a similar amount and intensity of exercise during the study period as during the baseline period;\n9. Maintain good living habits, have no history of alcoholism or alcohol dependence (ICD-10 diagnosis is F10)\n10. No new or recurring cardiovascular events (myocardial infarction, cerebral infarction, etc.) within half a year;\n11. No stent implantation plan within three months;\n12. Female subjects have not had sexual intercourse for 14 days before administration, and their blood tests indicate that they are not pregnant;\n13. Subjects of childbearing age agree to use highly effective contraceptive measures for at least 365 days from the time of NGGT006 administration.\n\nExclusion Criteria:\n\n1. Secondary hyperlipidemia;\n2. Use of other drugs or nutritional products that may affect blood lipids (such as fibrates) within 6 weeks;\n3. Have received low-density lipoprotein apheresis (LDL apheresis) within the past 2 months;\n4. Large weight fluctuations (≥5kg) in the past 2 months;\n5. Positive for hepatitis B surface antigen, hepatitis C, human immunodeficiency virus (HIV)，syphilis test or other infections (such as Epstein-Barr virus, Mycoplasma pneumoniae, tuberculosis virus, HPV, Chlamydia pneumoniae, respiratory syncytial virus, Adenovirus and coxsackievirus group B, etc.);\n6. Clinically significant abnormalities in liver function test: alanine aminotransferase (ALT) \\>2 × upper limit of normal (ULN) and\u002For aspartate aminotransferase (AST) \\>2 × ULN;\n7. RR at the baseline \\>160\u002F100mmHg (one repeated measurement is allowed);\n8. Uncontrollable myocardial infarction or heart failure, and those planning surgery within one year; or new acute coronary syndrome in the past six months;\n9. Diabetes diagnosed within 3 months or with poor control (HbA1c \\>9%);\n10. Abnormal thyroid function, or those using thyroid hormone replacement therapy but poorly controlled (TSH within the normal range for \\\u003C12 weeks);\n11. Acute or chronic renal insufficiency;\n12. Hemoglobin (Hb) \\\u003C 120g\u002FL (male), Hb \\\u003C 110 (female);\n13. Abnormal platelet counts or morphology;\n14. History or laboratory tests suggestive of thrombosis;\n15. Had contraindications to glucocorticoid (e.g., epilepsy, severe schizophrenia, active peptic ulcer)；\n16. Used systemic glucocorticoid treatment within 6 weeks before enrollment;\n17. Life expectancy less than 1 year;\n18. Suffering from malignant tumors such as liver cancer; liver fibrosis;\n19. Previous gene therapy treatment;\n20. Hypersensitivity to AAV preparations (for example trehalose) or cortisone or immunosuppressants (sirolimus, rituximab, tacrolimus);\n21. Suffering from immunodeficiency disease\n22. Participation in any other clinical trial within 3 months;\n23. Breastfeeding females;\n24. Any other condition that may not be appropriate for the study in the opinion of the Investigator.","55 Years",{"count":108,"type":21},9,[110],"EARLY_PHASE1","This is an early phase 1, open-label, single-center, dose-escalation pilot trial to evaluate the safety and efficacy of an intravenous infusion of NGGT006 in patients with refractory Hypercholesterolemia diagnosed by gene testing for familial hypercholesterolemia. NGGT006 uses adeno-associated virus (AAV) as a vector, carrying a liver specific promoter and codon optimized human LDLR gene, driving the expression of LDLR protein with normal function and promoting the clearance of low-density lipoprotein cholesterol (LDL-C).",[113,114],"Refractory Hypercholesterolemia","Familial Hypercholesterolemia",[116,117],"Gene therapy","Low-density lipoprotein cholesterol","NOT_YET_RECRUITING","2024-04-16",{"date":121,"type":38},"2024-04-17",{"date":123,"type":21},"2024-06-01",{"date":125,"type":21},"2029-03-01",{"name":44,"class":45},{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":134,"minAge":17,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":22,"phases":137,"briefSummary":139,"conditions":140,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":76},"100506310","phase-2-optimization-of-postoperative-adjuvant-therapy-for-cervical-cancer-based-on-mrdminimal-residual-disease-100506310","NCT05872724","Optimization of Postoperative Adjuvant Therapy for Cervical Cancer Based on MRD(Minimal Residual Disease)","Clinical Study on Optimization of Postoperative Adjuvant Therapy for Cervical Cancer Based on MRD","Inclusion Criteria:\n\n1. Patients with histopathological and clinical (FIGO 2018) stage ⅠB2 \\~II A2 cervical cancer.\n2. Above the age of 18.\n3. General status: ECOG score 0-2.\n4. Be able to understand the research scheme, voluntarily participate in the study, and sign the informed consent.\n5. Good compliance, able to cooperate with the collection of specimens at each node and provide corresponding clinical information.\n\nExclusion Criteria:\n\n1. Suffering from other malignant tumors.\n2. Do not receive the specified treatment or change the treatment regimen before the disease progresses.\n3. The study cannot be followed up according to the defined clinical follow-up period.\n4. Unable to accept or provide CT or other designated therapeutic evaluation means.\n5. Have an autoimmune disease.","FEMALE",{"count":136,"type":21},32,[138],"PHASE2","This study is a prospective cohort clinical trial that aims to investigate the safety and efficacy of a combined chemoradiotherapy and immunotherapy treatment for early postoperative cervical cancer. Specifically, this study seeks to evaluate the ability of MRD-based screening to detect and monitor changes in MRD status at different stages of treatment, its potential for use in monitoring patient recurrence rates and in prognosis evaluation. In addition, this study will investigate the safety and effectiveness of chemoradiotherapy combined with immunotherapy as a postoperative adjuvant therapy for patients identified to be at risk of early cervical cancer based on MRD screening.",[141],"Cervical Cancer","2023-05-14",{"date":144,"type":38},"2023-05-24",{"date":146,"type":38},"2023-01-16",{"date":148,"type":21},"2028-12-30",{"name":44,"class":45},""]